Pliant Therapeutics, Inc.
PLRX
$1.48
$0.010.68%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | 0.00 |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | 0.00 |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | 0.00 |
| SG&A Expenses | 14.53M | 14.26M | 15.02M | 15.25M | 13.85M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 53.32M | 62.01M | 60.64M | 52.39M | 47.04M |
| Operating Income | -53.32M | -62.01M | -60.64M | -52.39M | -47.04M |
| Income Before Tax | -49.73M | -57.76M | -55.85M | -46.96M | -41.11M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -49.73M | -57.76M | -55.85M | -46.96M | -41.11M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -49.73M | -57.76M | -55.85M | -46.96M | -41.11M |
| EBIT | -53.32M | -62.01M | -60.64M | -52.39M | -47.04M |
| EBITDA | -52.86M | -61.48M | -60.02M | -51.88M | -46.57M |
| EPS Basic | -0.82 | -0.95 | -0.93 | -0.78 | -0.69 |
| Normalized Basic EPS | -0.51 | -0.59 | -0.58 | -0.49 | -0.43 |
| EPS Diluted | -0.82 | -0.95 | -0.93 | -0.78 | -0.69 |
| Normalized Diluted EPS | -0.51 | -0.59 | -0.58 | -0.49 | -0.43 |
| Average Basic Shares Outstanding | 60.85M | 60.73M | 60.38M | 60.18M | 59.90M |
| Average Diluted Shares Outstanding | 60.85M | 60.73M | 60.38M | 60.18M | 59.90M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |